Stocks quoted in this article:
In the first session of December, U.S. stocks have erased early gains, following disappointing U.S. manufacturing data for November. Here's a quick update on today's latest brokerage notes, including adjustments for BlackBerry inventor Research In Motion Limited (USA) (NASDAQ:RIMM - 11.53), shipping specialist FedEx Corporation (NYSE:FDX – 88.45), and medical devices developer Boston Scientific Corporation (NYSE:BSX - 5.58).
- Early this morning, analysts at Canaccord Genuity cut their view of RIMM to "sell" from "hold," claiming that the company's BlackBerry 10 is too little, too late. Even though RIMM has sawed off roughly 20% in 2012, the shares have outpaced the S&P 500 Index (SPX) by 76 percentage points during the past three months, and have tacked on 86.5% since dropping to a nine-year low of $6.22 on Sept. 22. Consequently, the security's Relative Strength Index (RSI) now resides at 70 -- in overbought territory -- suggesting RIMM may be due for a near-term pullback.
- Next up … Following Friday's announcement that FDX will raise its 2013 shipping rates by an average of 4.9%, Citigroup lowered its price target by $5 to $103 (but kept its "buy" rating intact). This newly adjusted target sits near the average 12-month price target of $105.30, which represents a 17.6% premium to Friday's closing price of $89.53. Furthermore, FDX hasn't traded in the $105 neighborhood since October 2007.
- BSX was greeted with an upgrade to "outperform" from "market perform" at JMP Securities. The firm based this note on what it sees as potential for a "multi-year growth period" due to BSX's new line of surgical devices for the heart. If this conjecture proves accurate, additional upgrades among brokerages could boost the stock's modest 3.7% year-to-date gain. Currently, there are five "buy" or better suggestions, versus 15 tepid "holds" and one "strong sell" recommendation.